NCT00750178View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2004

Primary Completion Date

August 1, 2005

Study Completion Date

November 1, 2005

Conditions
Cancer, Advanced
Interventions
DRUG

vorinostat (MK0683 )

"Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28~Total treatment period is 28 days"

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00750178 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008) | Biotech Hunter | Biotech Hunter